TY - JOUR
T1 - Tranexamic acid to reduce operative blood loss in brain tumor surgery
T2 - A meta-analysis
AU - Prastikarunia, Resi
AU - Wahyuhadi, Joni
AU - Susilo, Rahadian Indarto
AU - Haq, Irwan Barlian Immadoel
N1 - Publisher Copyright:
© 2021 Published by Scientific Scholar on behalf of Surgical Neurology International.
PY - 2021
Y1 - 2021
N2 - Background: Major blood loss during neurosurgery may result in a variety of complications, such as potentially fatal hemodynamic instability. Brain tumor and skull base surgery is among the high bleeding risk procedures. Tranexamic acid (TXA) has been found to reduce bleeding events in various fields of medicine. Methods: We searched for all randomized controlled trials published in English or Bahasa which compared the use of TXA with placebo in brain tumor surgery. The studies should include adult patients with intracranial tumor who received TXA before skin incision. The primary and secondary outcomes are intraoperative blood loss and the need of transfusion. Results: This meta-analysis included a total of 200 patients from three studies. TXA resulted in less blood loss with pooled mean difference of −292.80 (95% CI, −431.63, −153.96, P<0.05). The need of transfusion was not significant between TXA and control group (pooled mean difference −85.36, 95% CI, −213.23 – (42.51), P=0.19). Conclusion: TXA reduced the volume of blood loss but did not reduce the need of blood transfusion.
AB - Background: Major blood loss during neurosurgery may result in a variety of complications, such as potentially fatal hemodynamic instability. Brain tumor and skull base surgery is among the high bleeding risk procedures. Tranexamic acid (TXA) has been found to reduce bleeding events in various fields of medicine. Methods: We searched for all randomized controlled trials published in English or Bahasa which compared the use of TXA with placebo in brain tumor surgery. The studies should include adult patients with intracranial tumor who received TXA before skin incision. The primary and secondary outcomes are intraoperative blood loss and the need of transfusion. Results: This meta-analysis included a total of 200 patients from three studies. TXA resulted in less blood loss with pooled mean difference of −292.80 (95% CI, −431.63, −153.96, P<0.05). The need of transfusion was not significant between TXA and control group (pooled mean difference −85.36, 95% CI, −213.23 – (42.51), P=0.19). Conclusion: TXA reduced the volume of blood loss but did not reduce the need of blood transfusion.
KW - Brain tumor
KW - Intraoperative bleeding
KW - Tranexamic acid
KW - Transfusion
UR - http://www.scopus.com/inward/record.url?scp=85110724082&partnerID=8YFLogxK
U2 - 10.25259/SNI_19_2021
DO - 10.25259/SNI_19_2021
M3 - Article
AN - SCOPUS:85110724082
SN - 2152-7806
VL - 12
JO - Surgical Neurology International
JF - Surgical Neurology International
ER -